DSCSA Compliance: What It Requires of a Distributor

DSCSA (the Drug Supply Chain Security Act, enacted 2013 as Title II of the Drug Quality and Security Act) is the U.S. federal law that governs how ownership of a human prescription drug product must be documented and verified as it moves through the wholesale distribution chain. For a distributor, DSCSA compliance is not a single certificate or a general safety claim — it is a specific, ongoing set of documentation, verification, and investigation duties that apply to every transaction, and a buyer evaluating a distributor’s claim to be ‘DSCSA compliant’ should know what that claim actually has to cover before taking it at face value.

What DSCSA Requires at the Distributor Level

Three obligations sit at the center of distributor-level DSCSA compliance:

• Pass complete Transaction History, Transaction Information, and Transaction Statement (T3) at every change of ownership. Transaction History is the documented record of every prior sale of the product back to the manufacturer. Transaction Information identifies the product (proprietary/established name, dosage form, strength, container size, NDC, lot number, quantity) and the parties and date of the transaction. Transaction Statement is the seller’s certification that it is an authorized trading partner, received the product from an authorized trading partner, received the T3 for the product, did not knowingly ship a suspect or illegitimate product, has systems to comply with verification requirements, and did not knowingly provide false information. A distributor must both receive T3 on everything it buys and pass an updated, complete T3 forward on everything it sells — keeping data on file is not sufficient if it doesn’t also get forwarded to the next owner.
• Verify that trading partners are authorized. Before transacting, a distributor has to confirm the manufacturers, wholesalers, dispensers, and repackagers it deals with meet the law’s definition of an authorized trading partner (holding the required state and, where applicable, federal licensure/registration). Buying from or selling to an unauthorized trading partner is itself a compliance failure, independent of whether the product involved is genuine.
• Quarantine, investigate, and act on suspect or illegitimate product. If a distributor has reason to believe a product may be counterfeit, diverted, stolen, intentionally adulterated, unfit for distribution, or otherwise fraudulent, it must quarantine that product, investigate, and — if the investigation confirms the product is illegitimate — notify FDA and its trading partners and coordinate the product’s disposition. Reselling first and asking questions later is exactly what this duty exists to prevent.

The Shift From Lot-Level Paper Records to Unit-Level Electronic Tracing

DSCSA was written as a phased law, not a single compliance date. Early phases were satisfiable with lot-level data exchanged on paper or in simple electronic files. The law’s end-state goal — an electronic, interoperable system operating down to the individual saleable unit — is a materially higher bar: it requires serialized unit-level identifiers, trading partners exchanging that data in a common electronic format (industry practice has converged on GS1’s EPCIS standard), and the ability to verify a specific unit’s history on request rather than only a lot’s. FDA has used enforcement-discretion and stabilization-period guidance to phase in real-world compliance with this end state, and the exact current enforcement posture shifts as that guidance is updated — a distributor’s or a buyer’s honest answer to ‘are you fully unit-level interoperable today’ should reference where implementation actually stands at the time asked, not just the law’s original target date, and any specific current deadline should be checked against FDA’s own DSCSA guidance rather than assumed from an older article.

Why This Is a Different Compliance Domain Than Device Lot Traceability

CASRAI’s lab-equipment and lab-compliance content elsewhere covers device-side traceability — 21 CFR Part 820 device history/identification-and-traceability requirements, ISO 13485 quality-management traceability clauses, and Unique Device Identification (UDI) for medical devices. Those apply to a different regulated article (medical devices, not drugs), sit inside a different regulatory framework (FDA’s Quality System Regulation / QMSR and device-specific rules, not DSCSA), and are structured around a different unit of tracking (manufacturing lot/batch and device identifier, tied to design controls and recall capability) rather than DSCSA’s transaction-by-transaction chain-of-ownership model. A distributor that only handles devices has no DSCSA obligation at all; a distributor that handles both devices and prescription drugs is running two separate traceability compliance programs side by side, not one program that happens to cover both. Don’t accept device-side lot-traceability documentation as evidence of DSCSA compliance, or vice versa — they answer different questions.

What to Ask When Evaluating a Distributor’s DSCSA Compliance Claim

A distributor being generally reputable, or even generally licensed, is not the same as being able to demonstrate DSCSA compliance on request. Before relying on a vendor’s DSCSA claim:

• Ask how T3 data is exchanged, not just whether it is. ‘We keep records’ is a weaker claim than being able to name the format (EPCIS or equivalent) and show that T3 is actually forwarded to the buyer at the point of sale, not just archived internally.
• Ask about trading-partner verification as a documented process, not a one-time check. DSCSA requires ongoing verification, not a single onboarding step performed once and never revisited.
• Ask what happens when suspect product is identified. A distributor that cannot describe its own quarantine/investigation/notification workflow in concrete terms is describing an intention, not a compliance program.
• Confirm current wholesale-distributor licensure in every state the distributor ships into (state licensure is a separate but related requirement layered under the DSCSA authorized-trading-partner definition), and ask whether the distributor carries third-party wholesale-distributor accreditation (for example, through the National Association of Boards of Pharmacy) as independent verification rather than a self-attestation.

The general pattern is the same one that applies to any regulatory-compliance claim a vendor makes: a precise, checkable answer about a specific mechanism is worth more than an unqualified assurance of being ‘compliant.’

Related Terms

See also Good Distribution Practice (GDP), the broader storage/handling/transport framework DSCSA’s chain-of-custody requirements sit alongside, and Pharma Cold Chain Logistics, which covers a different (temperature) dimension of the same distribution chain.